Jubilant Expands European R&D Footprint Through Strategic Acquisition

Jubilant Biosys has acquired an 80% equity stake in JASMIN, a new company formed by Pierre Fabre. This acquisition includes an R&D center in France, enhancing Jubilant’s capabilities in Biologics and Antibody Drug Conjugates. The move strengthens Jubilant's European presence and enhances its market reach in the fast-growing ADC sector.

Jubilant Biosys, a notable player in drug discovery, has acquired a significant stake in JASMIN, a new entity formed through an agreement with Pierre Fabre. This strategic acquisition includes Pierre Fabre's R&D center in Saint-Julien-en-Genevois, bolstering Jubilant's capabilities in Biologics and Antibody Drug Conjugates.

With this move, Jubilant strengthens its European footprint, establishing a Center of Excellence within a booming pharmaceutical hub. The acquisition not only augments Jubilant's drug development services but also expands its market access in the fast-growing ADC segment, aiming at a market scale of $1.4 billion.

This partnership connects Jubilant with Pierre Fabre's seasoned team in ADC/XDC expertise, fostering innovation and collaboration. As part of its 'CRDMO Partner in Science' strategy, Jubilant is set to deliver more comprehensive services to its global clientele, enhancing its innovative solutions offering.